NIKKEI 225
29,068.63 +517.70 (+1.81%) HANG SENG
25,330.96 +368.37 (+1.48%) GOLD FUTURES
1,768.10 -29.80 (-1.66%) DOW
35,294.76 +382.20 (+1.09%) BTC-GBP
44,773.21 +318.96 (+0.72%) CMC Crypto 200
1,464.06 +57.32 (+4.07%)
Johnson & Johnson (JNJ)
After hours: 07:59PM EDT
| Previous close | 160.11 |
| Open | 161.03 |
| Bid | 161.45 x 800 |
| Ask | 161.49 x 1300 |
| Day's range | 160.44 - 161.81 |
| 52-week range | 133.65 - 179.92 |
| Volume | 6,918,407 |
| Avg. volume | 5,908,775 |
| Market cap | 424.767B |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | 28.49 |
| EPS (TTM) | 5.66 |
| Earnings date | 19 Oct 2021 |
| Forward dividend & yield | 4.24 (2.56%) |
| Ex-dividend date | 23 Aug 2021 |
| 1y target est | 187.17 |
- Motley Fool
Can Pfizer and GlaxoSmithKline Beat Johnson & Johnson's RSV Vaccine?
Johnson & Johnson (NYSE: JNJ) recently announced positive results from a phase 2 study of its RSV vaccine candidate. In this Motley Fool Live video recorded on Oct. 6, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not J&J set a high bar for Pfizer (NYSE: PFE) and GlaxoSmithKline (NYSE: GSK) to top.
- Motley Fool
3 Dividend Stocks to Buy If the Stock Market Crashes
Most stocks sink when the stock market itself plunges. Not only are their stocks available at a discount, but the lower share prices also allow you to lock in higher dividend yields. No one knows for sure whether the stock market will crash anytime soon.
- Motley Fool
Will Johnson & Johnson Win Authorization for Its COVID-19 Booster?
A U.S. Food and Drug Administration (FDA) advisory committee has reviewed Johnson & Johnson's (NYSE: JNJ) data supporting boosters of its COVID-19 vaccine. The FDA gets the final say in the matter, though. In this Motley Fool Live video recorded on Oct. 6, Motley Fool contributors Keith Speights and Brian Orelli discuss J&J's prospects for authorization of boosters.
